LONDON, UK (GlobalData), 23 May 2012 - Growing numbers of organ transplants are to be supported in the future by improved drug treatments, particularly in the field of kidney transplantation, according to a new report by pharmaceutical experts GlobalData.
The new report* states that Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) is expected to become increasingly common, leading to an increase in the number of kidney transplantation patients and therefore supporting growth of the transplantation drugs market. Surgical advances are also making organ transplantations simpler and less dangerous to the patient, thus developing stronger patient confidence in the procedure.
The existing kidney transplantation therapeutics market is strong, represented by 13 approved products. The drugs most commonly used for kidney transplantation are Calcineurin Inhibitors (CNIs), such as Sandimmune/Neoral (cyclosporine) and Prograf/Advagraf (tacrolimus); corticosteroids; antimetabolites such as Imuran (azathioprine), CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid)); mammalian Target of Rapamycin (mTOR) inhibitors such as Rapamune (sirolimus), and Zortress/Certican (everolimus); and antibodies such as Thymoglobulin (anti-thymocyte Globulin), Atgam (lymphocyte immune globulin), Orthoclone OKT3 (muromunab-CD3), Zenapax (daclizumab), and Simulect (basiliximab).
GlobalData has found that the kidney transplantation therapeutics market has significant unmet need despite its 13 existing treatment options, due to the poor safety profiles, high costs and low compliance rates associated with all current products. Consequently, there is scope for novel drugs which utilise other types of new technology, such as stem cell therapy and immunoglobulin therapy.
The kidney transplantation maintenance market has showed a recent decline, primarily due to the generic erosion of the most widely used immunosuppressant drugs approved for kidney transplantation maintenance. Prograf (tacrolimus) lost its patent protection in the US in 2008, in Europe in 2009, and in Japan in 2010. CellCept (mycophenolate mofetil) also lost its patent protection in 2009 in the US, and in 2010 in Europe.
However, the expected launch of promising molecules LCP-Tacro and Voclosporin in 2013 is expected to boost the future market. The strong kidney transplantation pipeline has 28 molecules in various phases of clinical development, and it is highly likely that the majority will be launched in the forecast period. Of these molecules, 22 trials are being sponsored by companies able to afford to plug significant funds into promising discoveries, with the majority of the drugs first-in-class and boasting novel mechanisms of action. These products are expected to create intense competition and make a significant commercial impact on the kidney transplantation market during the forecast period.GlobalData estimates that the global kidney transplantation market, comprising of the US, the UK, France, Germany, Italy, Spain and Japan, was worth $2,676m in 2011, and forecasts growth at a compound annual growth rate (CAGR) of 5.3% to $4,043.5m by 2019.
*Kidney Transplantation Therapeutics - Pipeline Assessment and Market Forecasts to 2019
This report is an essential source of information and analysis on the global kidney transplantation therapeutics market, identifying the key trends shaping and driving this global market. It also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global kidney transplantation therapeutics sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at firstname.lastname@example.org